Study type

Study type

Non-interventional study

Scope of the study

Disease epidemiology
Drug utilisation
Effectiveness study (incl. comparative)
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

GALCANEZUMAB
LASMIDITAN

Medical condition to be studied

Migraine
Population studied

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

60000
Study design details

Main study objective

The primary objective of this research is to monitor and understand changes in health care delivery, acute/preventive migraine medication use, and impact to people with migraine with the introduction of new classes of migraine medications

Outcomes

Address changes in health care delivery, migraine care, and outcomes from a baseline state (pre-/peri-approval of novel acute and preventive migraine medication classes) to a future state (post-approval of novel acute and preventive migraine medication classes), Compare cohorts of people with migraine on novel treatments compared with SOC treatments for migraine

Data analysis plan

Analyses are grouped into five general categories: cross-sectional cohort analyses, differences between cohort analyses, longitudinal follow-up analyses, linked claims, and non-migraine population analysis. Descriptive statistics will be conducted to provide summaries for all variables in each cohort and specific subgroups of interest. Continuous variables will be summarized as means with standard deviations, or medians and ranges, as appropriate. Categorical variables will be summarized as frequencies and percentages.